Breast cancer risk-assessment models

被引:108
作者
Evans, D. Gareth R. [1 ]
Howell, Anthony [2 ]
机构
[1] St Marys Hosp, Acad Unit Med Genet & Reg Genet Serv, Manchester M13 0JH, Lancs, England
[2] Univ Manchester, Christie Hosp, Dept Med Oncol, CRUK, Manchester M20 4BX, Lancs, England
关键词
BRCA2; MUTATION; FAMILY-HISTORY; REPLACEMENT THERAPY; CARRIER PROBABILITIES; PREDICTION MODELS; SEQUENCE-ANALYSIS; OPTIMAL SELECTION; WOMEN; ESTROGEN; GENE;
D O I
10.1186/bcr1750
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
There are two main questions when assessing a woman for interventions to reduce her risks of developing or dying from breast cancer, the answers of which will determine her access: What are her chances of carrying a mutation in a high-risk gene such as BRCA1 or BRCA2? What are her risks of developing breast cancer with or without such a mutation? These risks taken together with the risks and benefits of the intervention will then determine whether an intervention is appropriate. A number of models have been developed for assessing these risks with varying degrees of validation. With further improvements in our knowledge of how to integrate risk factors and to eventually integrate further genetic variants into these models, we are confident we will be able to discriminate with far greater accuracy which women are most likely to develop breast cancer.
引用
收藏
页数:8
相关论文
共 56 条
  • [1] Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme
    Amir, E
    Evans, DG
    Shenton, A
    Lalloo, F
    Moran, A
    Boggis, C
    Wilson, M
    Howell, A
    [J]. JOURNAL OF MEDICAL GENETICS, 2003, 40 (11): : 807 - 814
  • [2] Pregnancies, breast-feeding, and breast cancer risk in the international BRCA1/2 carrier cohort study (IBCCS)
    Andrieu, Nadine
    Goldgar, David E.
    Easton, Douglas F.
    Rookus, Matti
    Brohet, Richard
    Antoniou, Antonis C.
    Peock, Susan
    Evans, Gareth
    Eccles, Diana
    Douglas, Fiona
    Nogues, Catherine
    Gauthier-Villars, Marion
    Chompret, Agnes
    van Leeuwen, Flora E.
    Kluijt, Irina
    Benitez, Javier
    Arver, Brita
    Olah, Edith
    Chang-Claude, Jenny
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (08): : 535 - 544
  • [3] Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history:: A combined analysis of 22 studies
    Antoniou, A
    Pharoah, PDP
    Narod, S
    Risch, HA
    Eyfjord, JE
    Hopper, JL
    Loman, N
    Olsson, H
    Johannsson, O
    Borg, Å
    Pasini, B
    Radice, P
    Manoukian, S
    Eccles, DM
    Tang, N
    Olah, E
    Anton-Culver, H
    Warner, E
    Lubinski, J
    Gronwald, J
    Gorski, B
    Tulinius, H
    Thorlacius, S
    Eerola, H
    Nevanlinna, H
    Syrjäkoski, K
    Kallioniemi, OP
    Thompson, D
    Evans, C
    Peto, J
    Lalloo, F
    Evans, DG
    Easton, DF
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 72 (05) : 1117 - 1130
  • [4] Parity and breast cancer risk among BRCA1 and BRCA2 mutation carriers
    Antoniou, Antonis C.
    Shenton, Andrew
    Maher, Eamonn R.
    Watson, Emma
    Woodward, Emma
    Lalloo, Fiona
    Easton, Douglas F.
    Evans, D. Gareth
    [J]. BREAST CANCER RESEARCH, 2006, 8 (06)
  • [5] Assessing BRCA carrier probabilities in extended families
    Barcenas, CH
    Hosain, GMM
    Arun, B
    Zong, JH
    Zhou, XJ
    Chen, JF
    Cortada, JM
    Mills, GB
    Tomlinson, GE
    Miller, AR
    Strong, LC
    Amos, CI
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (03) : 354 - 360
  • [6] Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0
  • [7] Beral Valerie, 2003, Lancet, V362, P419
  • [8] BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes
    Berry, DA
    Iversen, ES
    Gudbjartsson, DF
    Hiller, EH
    Garber, JE
    Peshkin, BN
    Lerman, C
    Watson, P
    Lynch, HT
    Hilsenbeck, SG
    Rubinstein, WS
    Hughes, KS
    Parmigiani, G
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (11) : 2701 - 2712
  • [9] Optimal selection for BRCA1 and BRCA2 mutation testing using a combination of ′easy to apply′ probability models
    Bodmer, D.
    Ligtenberg, M. J. L.
    van der Hout, A. H.
    Gloudemans, S.
    Ansink, K.
    Oosterwijk, J. C.
    Hoogerbrugge, N.
    [J]. BRITISH JOURNAL OF CANCER, 2006, 95 (06) : 757 - 762
  • [10] Calle EE, 1996, LANCET, V347, P1713, DOI 10.1016/S0140-6736(96)90806-5